gdc
Immunotherapy

Changing the Conversation: Immunotherapy and Long-Term Survival

Dr Morganna Freeman discusses some of the ways immunotherapy has changed cancer care, including the expectation for long-term survival and how to treat patients in remission.
Video Library – January 10, 2019
Morganna Freeman, DO, FACP

Dr Morganna Freeman discusses some of the ways immunotherapy has changed cancer care, including the expectation for long-term survival and how to treat patients in remission.

Recommended For You
Immunotherapy
Why Target the Immune System?
By Colleen H. Erb, MSN, CRNP, ACNP-BC, AOCNP
The immune system attacks foreign substances by making large numbers of antibodies. These are proteins that attach to a specific protein on the cell called an antigen.
ImmunotherapyMultiple Myeloma
How CAR T-Cell Therapy Gave Cherie Rineker Her Life Back
By Kelsey Moroz
Chemotherapy for multiple myeloma had kept Cherie Rineker alive for 5 years, but then she realized she was slowly dying. So she embarked on a search for a clinical trial and by luck was able to join one. To her amazement, “What 2 stem-cell transplants and 13 other treatments had not been able to do in more than 65 months, CAR T-cell therapy did in less than 1 month,” she said.
Breast CancerFDA Approvals, News & UpdatesImmunotherapy
First Immunotherapy Approved for Patients with Advanced or Metastatic Triple-Negative Breast Cancer Expressing PD-L1
In March 2019, the FDA approved Tecentriq (atezolizumab), a PD-L1 inhibitor, in combination with Abraxane (paclitaxel protein-bound), for use in adults with locally advanced or metastatic triple-negative breast cancer whose tumors cannot be removed by surgery and express PD-L1, as identified by an FDA-approved test. This is the first FDA-approved immunotherapy for patients with advanced or metastatic triple-negative breast cancer.
Last modified: February 27, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country